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Purpose: To review the clinical outcomes of extended-field radiation therapy (EFRT) and to analyze prognostic factors
significant for survival in patients receiving EFRT for uterine cervical carcinoma with para-aortic node (PAN) metastasis.
Patients and methods: We retrospectively reviewed 90 patients with stage IB-IVA cervical cancer and PAN metastasis
between 1987 and 2012. Median age was 50 (range, 24–77). Patients received median 70.2 Gy (range, 56–93) to point
A and median 50.4 Gy (range, 45–60.4) to PAN over median 69 elapsed days (range, 43–182). Forty-six patients (51.1%)
received concurrent chemotherapy. Survival was calculated using the Kaplan–Meier method. We analyzed prognostic
factors for overall actuarial survival (OS) and progression-free survival (PFS) using a Cox regression method.
Results: The median follow-up period for surviving patients was 55 months (range, 3–252). Seventy patients (77.8%) had
complete remission. Forty-six patients experienced treatment failure as follows: 11 patients (12.2%) as local recurrence, 19
(21%) as regional recurrence and 33 (36.7%) as distant metastasis. The 5-yr OS and PFS were 62.6% and 43.9%, respectively.
Treatment response was the only statistically independent prognostic factors for OS (p= 0.04) and PFS (p< 0.001) on
multivariate analysis. Grade 3 or 4 hematologic gastrointestinal and urogenital toxicities were observed in about 10% of
patients.
Conclusions: Our institutional experiences showed that EFRT was an effective treatment for cervical cancer patients with
PAN metastasis. The addition of chemotherapy to EFRT seems to have uncertain survival benefit with higher hematologic
toxicity.
Keywords: Cervical cancer, Treatment outcome, Chemotherapy, Para-aortic lymph node, Extended-field radiation therapyIntroduction
Para-aortic node (PAN) metastasis is an important prog-
nostic factor, although the International Federation of
Gynecology and Obstetrics (FIGO) staging system of uter-
ine cervical cancer does not allow for the involvement of
nodes [1]. According to the Gynecologic Oncology Group,
biopsy-confirmed PAN involvement was found in 5% of
Stage IB patients, 17% of Stage IIB patients, and 25% of* Correspondence: ybkim3@yuhs.ac
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were reported [2].
Extended-field radiation therapy (EFRT) is conventionally
indicated for cervical cancer patients with grossly detected
common iliac or PAN metastasis. In several previous stud-
ies on EFRT, a 5-year overall survival rate of 29 – 32% was
reported [3-5]. In some prospective and retrospective trials
with EFRT plus concurrent chemotherapy, severe toxicity
of EFRT plus concurrent chemotherapy, including gastro-
intestinal or hematologic toxicity, was observed despite a
favorable survival rate [6-8]. Therefore, some investigators
have tried to reduce the toxicity of EFRT plus concurrent
chemotherapy using intensity-modulated radiotherapy orhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Yoon et al. Radiation Oncology  (2015) 10:18 Page 2 of 10low dose chemotherapy [9,10]. However, despite a large
number of small population studies, the effect of EFRT with
or without concurrent chemotherapy has still not been
elucidated.
The purpose of this study was to investigate the clinical
outcomes, including toxicity, treatment response, patterns
of failure, and survival, as well as to analyze prognostic
factors significant for survival, in patients receiving EFRT
for uterine cervical carcinoma with PAN metastasis.
Methods and materials
Patient selection and characteristics
This retrospective study received approval from the internal
review boards of the participating institution (IRB No. 4-
2014-0162). Between April 1987 and December 2012, 123
patients with cervical cancer and PAN metastasis were
treated with EFRT at our institution. Among them, 33
patients were excluded if any of the following conditions
were met: (1) stage IVB, (2) distant nodal metastasis in
inguinal, mediastinal or supraclavicular lymphatics, (3)
salvage, palliative, or postoperative RT, (4) induction or
post-RT chemotherapy, (5) incomplete RT due to patient
refusal. Consequently, 90 patients were included in this
retrospective study. Clinical staging was based on the FIGO
stage classifications updated in 2009 [11]. The procedure for
staging included a detailed history and a physical examin-
ation, common laboratory tests, standard chest radiographs,
intravenous pyelograms, barium enemas, X-ray examination
of the lungs and skeleton, cystoscopies, and sigmoidos-
copies. All patients underwent computed tomography (CT)
(57.8%) or magnetic resonance imaging (MRI) (63.3%) scans
to evaluate pelvic or para-aortic lymph node involvement.
Positron emission tomography (PET) or PET-CT scans were
performed in 21 patients (23.3%). In the image interpret-
ation of CT or MRI, the principal criterion for metastatic
node involvement was the axial diameter of the lymph node.
The presence of lymph nodes larger than 1 cm in the short-
axis dimension was considered to indicate metastatic node
involvement. Additionally, we regarded central necrosis as a
significant criterion for metastatic disease within the lymph
node [12]. In the image interpretation of PET or PET-CT, a
malignant lymphadenopathy was defined as follows: 1)
fluorodeoxyglucose (FDG) accumulation greater than liver
accumulation or similar to brain cortex accumulation, or 2)
standardized uptake value of a lesion that corresponded to
CT and did not decrease on the delayed PET image
compared with the initial PET image [13]. Para-aortic
lymph nodes were surgically assessed in 7 patients (7.8%).
Histologic classification was based on the World Health
Organization classifications (Geneva, Switzerland).
Radiotherapy
All patients received a combination of external EFRT and
high-dose-rate intracavitary brachytherapy (HDR-ICR). Weused the box technique with parallel opposing fields for 87
patients or the two-field technique with antero-posterior
fields for 3 patients. For para-aortic irradiation, we defined
the T11-T12 or T12-L1 interspace covering the entire PAN
as the superior border, 2 cm from the front of the vertebral
body or enlarged lymph nodes as the anterior border, and
the midline of the vertebral body as the posterior border,
respectively. For whole pelvic irradiation, we defined the in-
ferior border of the obturator foramen (if distal vaginal was
not involved) or 2 cm below the lowest extent of the pri-
mary tumor (if there was distal vaginal invasion) as the in-
ferior border, and 1.5 cm to 2 cm from the true bony pelvis
as the lateral border in AP-PA fields. External EFRT was
delivered using a 10-MV linear accelerator with a dose of
1.8-2 Gy per fraction, 5 times per week. Midline shielding
with a 4 cm-width was performed after the delivery of 26.0
to 45 Gy based on treatment response. This was followed
by HDR-ICR using a remote afterloading system with a
Ralstron 303 Co-60 source (Shimadzu, Kyoto, Japan) from
1979 to 1997, or a Gamma-Med II Ir-192 source
(Sauerwein, Haan, Germany) from 1989 to 2006, or
Multisource® Ir-192 source (Eckert & Ziegler BEBIG,
Berlin, Germany) from 2007 onward. The total dose of
HDR-ICR was 20–48 Gy, with 3 or 5 Gy per fraction,
which was prescribed to point A. Overall, a 3 Gy per frac-
tion with a median fraction number of 10 (range, 8–16) was
prescribed for 43 patients and a 5 Gy per fraction with a me-
dian fraction number of 6 (range, 4–8) was administered to
the others. After the completion of HDR-ICR, patients were
administered a second course of external EFRT with midline
shielding to a total external beam dose of 45 to 54 Gy. For
patients with persistent residual disease, which was identi-
fied on pelvic examination and imaging studies performed
at 1 month after planned EFRT and HDR-ICR, boost irradi-
ation to the parametrium, pelvic wall, and involved node
was performed. The median dose of boost irradiation was 9
Gy (range, 5.4-16 Gy).
Chemotherapy
Platinum single-agent or platinum-based doublet regimens
were used. For concurrent chemoradiation (CCRT), proto-
cols included two treatment schemes. One scheme was
composed of three chemotherapy cycles administered at the
beginning of the first, fourth, and seventh weeks of RT [14],
and the regimen consisted of cisplatin (70 mg/m2) or car-
boplatin (area under the curve (AUC), 4) followed by five
consecutive daily infusions of 5-FU (1000 mg/m2/day).
Weekly administration of cisplatin (40 mg/m2) or carbo-
platin (AUC, 2) during RT has been performed since the
publication of randomized trials [15].
Follow-up
During treatment, adverse effects and performance levels
were monitored weekly. After completion of treatment,












Squamous cell carcinoma (SCC) 84 93.3
Large cell keratinizing 18 20
Large cell non-keratinizing 47 52.2
Large cell, not specified 3 3.3
SCC, not specified 14 15.6















Not confirmed 47 52.2
Primary tumor size (cm)
Median 5
Range (2–10)
Pelvic LN involvement 73 81.1








Table 1 Patient characteristics (Continued)
Treatment period
Before 2000 52 57.8
2000-present 38 42.2
Abbreviation: ECOG Eastern Cooperative Oncology Group performance.
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for the first 2 years, and every 6 months thereafter. Acute
treatment-related hematologic toxicities were defined ac-
cording to the National Cancer Institute Common Termin-
ology Criteria for Adverse Events, version 4.0. Acute
toxicities were evaluated from the start of treatment to 3
months following the completion of treatment. Depending
on the severity and duration of toxicity, treatment was
interrupted until the patient recovered. Late treatment-
related toxicities were assessed using the Late Radiation
Morbidity Scoring Scheme of the Radiation Therapy On-
cology Group and the European Organization for Research
and Treatment of Cancer. Late radiation toxicities develop-
ing later than 6 months after the completion of treatment
were grouped into rectal, bladder, small bowel, and other
complications.
We defined a complete remission (CR) as 100% decrease
of gross tumor on clinical evaluation or radiologic images.
Partial response (PR) and progressive disease (PD) were de-
fined as ≥ 50% decrease and > 25% increase of primary gross
tumor, respectively. Anything else was categorized as stable
disease. We evaluated treatment responses by performing
history taking, physical and pelvic examinations, and im-
aging studies, such as MRI or CT scan, at 3 months after
completion of all treatments. The follow-up imaging studies
were performed routinely at 1, 3, 6, 12, 18, and 24 months
after treatment completion, and once a year thereafter. We
defined local recurrence as any relapse or persistent disease
at the cervix, vagina, parametrium, or pelvic wall. Regional
recurrence was defined as node relapse within the RT field.
Although PAN relapse is considered as a distant metastasis
in the TNM staging system, PAN relapse was classified as a
regional recurrence in this study. We defined distant metas-
tasis as relapse outside the RT field.
Statistical analysis
Total dose to point A (Gy) was calculated by combining
the dose of external beam irradiation before midline
shielding and the total dose to point A in HDR-ICR.
Overall actuarial survival (OS) and progression-free sur-
vival (PFS) were calculated using the Kaplan–Meier
method and differences in survival rates were compared
by the log-rank test. The OS time was calculated from
the date of RT start to the date of death or last follow-
up. The PFS time was calculated from the date of RT
start to the date of disease progression, relapse, initiation
of new unplanned anticancer therapy, disease-related
Table 3 Patterns of failure
Patterns of failure n (%)
Local recurrence 11 12.2
Cervix 7 7.8
Vagina 3 3.3
Parametrium/pelvic wall 2 2.2
Regional recurrence 19 21
Pelvic lymph node 10 11.1
Paraaortic lymph node 13 14.4
Distant metastasis 33 36.7








Table 2 Treatment characteristics
Characteristics n (%)
Radiotherapy field
Whole pelvis and lower para-aortic lymphatics 4 4.4
Whole pelvis and entire para-aortic lymphatics 86 95.6
Chemotherapy
None 44 48.9
Concurrent chemotherapy 46 51.1
Weekly cisplatin or carboplatin 24 26.6
Cisplatin or carboplatin followed by 5-FU 22 24.5
Total dose to point A (Gy)
Median 70.2
Range (56–93)
Interquartile range (75th and 25th percentiles) 14.4 (80.4,66)
Total dose to para-aortic lymphatics
Median 50.4
Range (45–60.4)




Interquartile range (75th and 25th percentiles) 20 (80, 60)
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for OS and PFS using a Cox regression method. Signifi-
cant variables on univariate analysis were utilized for
multivariate analysis to establish independent prognostic
factors for OS and PFS. Differences in nominal variables
were compared using Pearson’s χ2 test or Fisher's exact
test. We analyzed difference in continuous variables
using the Mann–Whitney U test. We considered statis-
tical significance as p value ≤ 0.05.
Results
Patient and treatment characteristics
All patient and treatment characteristics are listed in Tables 1
and 2, respectively. Patients received a median of 70.2 Gy to
point A and a median of 50.4 Gy to PAN over a median of
69 elapsed days. Forty-six patients (51.1%) received concur-
rent chemotherapy.
Treatment-related toxicities
Fourteen patients (15.6%) exhibited grade 3 or 4 acute
leukopenia, 12 (13.3%) exhibited grade 3 or 4 acute anemia,
and 12 (13.3%) exhibited grade 3 or 4 acute throm-
bocytopenia. Grade 3 late gastrointestinal and urogenital
toxicities were observed in 8 (8.9%) and 3 patients (3.3%),
respectively. There was no grade 5 acute or late treatment-
related toxicity.
Treatment responses, patterns of failure, and survival
analyses
Seventy patients (77.8%) had CR and 20 patients (22.2%)
had PR. No SD or persistent disease was observed in any
patient. For PAN metastasis only, CR was observed in 75
patients (83.3%) and PR in 15 patients (16.7%). Forty-six
patients experienced treatment failure (Table 3).
The median follow-up period for surviving patients was
55 months (range, 3–252). The 5-year OS and PFS for all
patients were 62.6% and 43.9%, respectively. In univariate
analysis, ECOG PS (0 vs. 1 or 2, 5-yr OS 72.3% vs. 44.5%,
p = 0.04) and treatment response (CR vs. PR, 5-yr OS
68.8% vs. 35.8%, p = 0.01) showed a significant effect on
OS. Using multivariate analysis, treatment response was the
only statistically significant factor for OS (p = 0.04, hazard
ratio (HR) 0.43, 95% confidence interval (95% CI) 0.19-0.98,
Table 4 and Figure 1a). PFS was significantly associated
with ECOG PS (0 vs. 1 or 2, 5-yr PFS 54.4% vs. 23.9%,
p = 0.02) and treatment response (CR vs. PR, 5-yr PFS
55.0% vs. 0%, p < 0.001) in the univariate analysis, and
tumor shape showed significant trends for worse PFS. In
the multivariate analysis, only treatment response had a
significant influence on PFS (p < 0.001, HR 0.3, 95% CI
0.16-0.58, Table 4 and Figure 1b). Treatment response (CR
vs. PR) in PAN metastasis only was also associated signifi-
cantly with OS (HR 0.25, 95% CI 0.11-0.58, p = 0.001) and
PFS (HR 0.27, 95% CI 0.14-0.54, p < 0.001).
Table 4 Prognostic factors on overall survival and progression-free survival by Cox proportional-hazards model
Overall survival Progression-free survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
Variables HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age (<50 vs. ≥50) 1.21 (0.59-2.51) 0.61 1.24 (0.69-2.21) 0.47
ECOG PS (0 vs. 1 or 2) 0.45 (0.22-0.95) 0.04 0.53 (0.25-1.12) 0.1 0.48 (0.27-0.87) 0.02 0.57 (0.31-1.03) 0.06
Tumor shape (exophytic vs. infiltrative) 1.75 (0.85-3.64) 0.13 1.75 (0.98-3.14) 0.06 1.67 (0.93-2.99) 0.09
Tumor size (<5 vs. ≥5 cm) 0.67 (0.3-1.47) 0.31 0.72 (0.39-1.33) 0.29
Parametrial involvement (no vs. yes) 0.4 (0.1-1.7) 0.22 0.5 (0.18-1.39) 0.18
Endocervical extension (others vs. yes) 1.85 (0.82-4.17) 0.14 1.47 (0.8-2.7) 0.22
Pelvic nodal involvement (no vs. yes) 0.78 (0.32-1.91) 0.58 0.71 (0.34-1.47) 0.35
Hydronephrosis (no vs. yes) 1.21 (0.42-3.5) 0.72 0.82 (0.4-1.65) 0.57
Stage (IB vs. IIB vs. IIIA-IVA) Referent 0.38 (0.09-1.7) 0.45 Referent 0.45 (0.15-1.3) 0.32
0.9 (0.42-1.92) 0.81 (0.44-1.49)
Radiotherapy duration (<10 vs. ≥10 weeks) 0.59 (0.28-1.23) 0.16 0.62 (0.35-1.12) 0.11
Doses to point A (<75 vs. ≥75 Gy) 0.87 (0.42-1.8) 0.71 0.64 (0.36-1.15) 0.14
Doses to PAN (<50.4 vs. ≥50.4 Gy) 1.09 (0.46-2.55) 0.85 0.75 (0.35-1.6) 0.45
Treatment period (<2000 vs. ≥2000) 1.25 (0.59-2.65) 0.56 0.98 (0.54-1.76) 0.95
Treatment response (CR vs. PR) 0.36 (0.16-0.81) 0.01 0.43 (0.19-0.98) 0.04 0.27 (0.14-0.51) <0.001 0.3 (0.16-0.58) <0.001
Concurrent chemotherapy (no vs. yes) 1.23 (0.59-2.54) 0.59 0.88 (0.49-1.57) 0.65
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Figure 1 Kaplan–Meier curves of (a) 5-year overall survival rate (log rank test p = 0.01) and (b) progression-free survival rate (log rank
test p < 0.001) according to the treatment response.
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benefits?
The addition of concurrent chemotherapy was not re-
lated to OS or PFS in our univariate analysis (Table 4
and Figure 2). Comparing toxicities, we observed severeacute hematologic toxicity (grade 3 to 4) significantly
more often in patients receiving EFRT plus concurrent
chemotherapy then in those receiving EFRT alone
(Table 5). Although severe acute toxicity upon the
















44 39 32 25 25 23 21 18 18 16 8
46 43 40 32 28 26 23 20 18 16 9
Log rank test 
p value = 0.58
EFRT alone
EFRT plus concurrent 
chemotherapy
















44 37 28 22 19 18 15 14 13 11 6
46 38 30 25 21 15 14 12 12 11 6
Log rank test 
p value = 0.65
EFRT alone
EFRT plus concurrent 
chemotherapy
EFRT alone
EFRT plus concurrent 
chemotherapy
Figure 2 Kaplan–Meier curves of (a) 5-year overall survival rate (log rank test p = 0.58) and (b) progression-free survival rate (log rank
test p = 0.65) according to the addition of concurrent chemotherapy to EFRT.
Yoon et al. Radiation Oncology  (2015) 10:18 Page 7 of 10difference in treatment duration (p = 0.18, median 67 vs.
71 days), patients showing severe acute hematologic tox-
icity in the EFRT plus chemotherapy group showed longer
treatment durations (median 81 days, 43–182) than the
others (median 64 days, 47–129, p < 0.001). Radiation-
induced proctitis, cystitis, enteritis, and vesicovaginalfistula were observed as severe late toxicities. The interval
between the start of treatment and the appearance of
toxicities was a median of 15 months; the interval in the
EFRT plus chemotherapy group was shorter than that for
the EFRT alone group (median 13 vs. 27 months, respec-
tively). There was no significant difference in treatment
Table 5 Treatment-related toxicity according to
concurrent chemotherapy in extended-field radiation
therapy






Leukopenia 0 (0.0) 14 (30.4) <0.001
Anemia 0 (0.0) 12 (26.1) <0.001
Thrombocytopenia 0 (0.0) 12 (26.1) <0.001
Late
Rectal 4 (9.1) 4 (8.7) 1
Bladder 3 (6.8) 0 (0.0) 0.11
Small bowel 0 (0.0) 1 (2.2) 1
Vagina vault necrosis 0 (0.0) 0 (0.0) -
Abbreviation: CTx concurrent chemotherapy.
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vs. 80.4% and 19.6% in EFRT plus concurrent chemothe-
rapy, p = 0.42) or patterns of failure according to addition
of chemotherapy (Additional file 1: Table S1).
Discussion
This study showed that EFRT was an efficient treatment
for uterine cervical cancer with involved PAN, with a 5-
year OS of 62.6% and PFS of 43.9%. Treatment response
was an independent prognostic factor for survival. The
addition of concurrent chemotherapy to EFRT did not
affect treatment response, patterns of failure, OS, or
PFS, but rather, was associated with severe treatment-
related toxicity.
Although patients who underwent EFRT alone were
irradiated with a median of 54 Gy without a radio-
sensitizing chemotherapeutic agent, treatment response
rates were not different from patients receiving a median
of 50.4 Gy in EFRT plus concurrent chemotherapy. A
previous study demonstrated that concurrent chemo-
therapy did not affect overall survival in isolated PAN
recurred cervical cancer patients receiving a median of
50.8 Gy of RT to PAN (p = 0.69) [16]. Therein, a total
dose of ≥ 51 Gy tended to show higher survival than that
of <51 Gy (p = 0.07). Based on that previous study, we
also considered that 54 Gy of EFRT alone would be
sufficient to control PAN metastasis without radio-
sensitizing chemotherapy. Nevertheless, further study is
necessary.
For patients initially diagnosed with PAN metastasis, the
efficacy of concurrent chemotherapy seems to be uncer-
tain. Since Stryker et al. reported that cisplatin-based
chemotherapy may be beneficial [3], many studies have
continued to report favorable outcomes, despite more
acute severe hematologic and gastrointestinal toxicity
[7-9,17,18]. In reviewing our results, we did not observe asignificant survival benefit for the addition of concurrent
chemotherapy to EFRT, although the group that received
EFRT alone included more patients with disease of
advanced stage (p < 0.001, Additional file 1: Table S2).
This implies that survival benefit of EFRT plus concurrent
chemotherapy is insignificant for uterine cervical cancer
with PAN metastasis, suggesting that more effective che-
motherapeutic regimen and scheme would be required.
However, along with no difference in PFS according to
the addition of chemotherapy, the OS rates between
EFRT alone and EFRT plus concurrent chemotherapy
also showed no statistically significant difference. Due to
the different periods of treatment according to the
addition of chemotherapy (Additional file 1: Table S2), we
questioned whether differences in therapeutic standards,
such as salvage treatment, induced by the treatment year
could affect survival. Advances in RT [19-21] and chemo-
therapy [22,23] over the years have increased the success
rates of salvage treatments [24,25]. In this study, patients
treated with EFRT plus concurrent chemotherapy received
more salvage treatments (80.0% vs. 52.4%, p = 0.047), es-
pecially salvage chemotherapy (64% vs. 23.8%, p = 0.006),
after relapse (Additional file 1: Table S3). In the survival
analysis of relapsed patients only, patients receiving salvage
treatment showed significantly improved OS, compared to
those receiving only conservative care (median OS 51 vs.
13 months, p < 0.001, Additional file 2: Figure S1). There-
fore, it is possible that different treatment years may result
in survival differences according to the addition of chemo-
therapy in this study. The effect of additional chemothe-
rapy to EFRT in uterine cervical cancer with metastatic
PAN warrants investigation via a randomized clinical trial.
However, since enrolling participants in an EFRT alone
group in a prospective trial would be difficult, we are lim-
ited to indirect investigations through retrospective trials.
Special considerations are needed to understand our
findings because of several drawbacks. Since this study is a
retrospective review covering a long period (over 20
years), heterogeneity of patient characteristics might have
confused diagnosis, treatment, follow-up, and our results,
including treatment response and toxicity. Viewed in this
light, the most important consideration is the accuracy of
the PAN metastasis diagnosis. PAN metastasis was patho-
logically confirmed in a small number of patients of this
study. Most cases depended on several imaging studies,
including CT, MRI, PET, and PET-CT, due to the develop-
ment of imaging tools over a long time [26-29]. However,
as all patients underwent CT or MRI scans in this study,
we expect that there would not be many differences in
initial staging of lymph node involvement, despite a long
treatment period. As well, the long period could have
affected whether or not concurrent chemotherapy was
undertaken: the benefits of cisplatin-based concurrent che-
moradiotherapy were reported in 1999 [30]. Accordingly,
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only 9.1% of patients, and most patients were treated with
EFRT plus concurrent chemotherapy. Accordingly, we
evaluated treatment period as a prognostic factor in the
univariate and multivariate analyses of survival rates. How-
ever, treatment period did not affect OS and PFS signifi-
cantly. Chemotherapeutic regimens and schemes were also
heterogeneous, which might have influenced treatment
outcomes. On prognostic factors analysis using a Cox re-
gression method confined to patients receiving concurrent
chemotherapy, difference in chemotherapy scheme was
not a significant prognostic factor for OS and PFS (data
not shown). Since all patients who underwent EFRT plus
concurrent chemotherapy in this study received platinum-
based regimens [30,31] and since the addition of chemo-
therapy and difference in chemotherapy scheme did not
affect survival, we do not consider the heterogeneity of
chemotherapeutic regimens and schemes to have affected
OS and PFS.
In conclusion, we suggest that EFRT with or without
concurrent chemotherapy can be an effective treatment
for cervical cancer patients with para-aortic node metas-
tasis. Treatment response was a significant prognostic
factor for OS and PFS, respectively. Our findings showed
the controversial effects of the addition of concurrent
chemotherapy to EFRT. Although they should be inter-
preted cautiously, due to the heterogeneity in this study,
our findings deserve consideration, since performing a
randomized clinical trial would be impractical.
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Additional file 1: Table S1. Patterns of failure according to the
addition of chemotherapy. Table S2. Patient and treatment
characteristics according to the addition of chemotherapy. Table S3.
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receiving salvage treatment showed significantly improved overall
survival rates compared to those receiving only conservative care after
relapse (median OS 51 vs. 13 months, p < 0.001).
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